Several anti-PD-1/PD-L1 agents have been approved by the FDA for the treatment of advanced non-small cell lung cancer (NSCLC), both as first-line therapies (alone or in combination with chemotherapy or other ICIs) and in later lines of treatment. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.